Loading...
We have set up our new Discord server! Share your feedback and find like-minded people! Join our Discord
- Ticker
- GRF-P.MC
- Price
- 7.86
- Stock movement up
- +0.13 (1.68%)
- Company name
- Grifols SA
- Exchange
- (MC ,
- Currency
- EUR )
- Sector
- Other >Other
- Market cap
- -
- Ent value
- 11.61B
- Price/Sales
- -
- Price/Book
- -
- Div yield
- -
- Div growth
- -
- Growth years
- -
- FCF payout
- -
- Trailing P/E
- -
- Forward P/E
- 6.72
- PEG
- -
- EPS growth
- -24.07%
- 1 year return
- 6.50%
- 3 year return
- -
- 5 year return
- -
- 10 year return
- -
Last updated: 2025-12-12
DIVIDENDS
GRF-P.MC does not pay dividends or no data was received
VALUATION
Valuation Ratios
Loading...
Valuation Ratios data
| Trailing P/E | - |
| Price to OCF | - |
| Price to FCF | - |
| Price to EBITDA | - |
| EV to EBITDA | - |
Valuation (Sales/Book Value)
Loading...
Valuation (Sales/Book Value) data
| Price to Sales | - |
| Price to Book | - |
| EV to Sales | 1.55 |
FINANCIALS
Per share
Loading...
Per share data
| Current share count | - |
| EPS (TTM) | - |
| FCF per share (TTM) | - |
Income statement
Loading...
Income statement data
| Revenue (TTM) | - |
| Gross profit (TTM) | - |
| Operating income (TTM) | - |
| Net income (TTM) | - |
| EPS (TTM) | - |
| EPS (1y forward) | 1.17 |
Margins
Loading...
Margins data
| Gross margin (TTM) | - |
| Operating margin (TTM) | - |
| Profit margin (TTM) | - |
Balance Sheet
Loading...
Please create a free account or log in to access this chart
Balance Sheet data
| Cash | 558.69M |
| Net receivables | 748.96M |
| Total current assets | 5.25B |
| Goodwill | 6.86B |
| Intangible assets | 2.74B |
| Property, plant and equipment | 6.57B |
| Total assets | 19.77B |
| Accounts payable | 878.68M |
| Short/Current long term debt | 0.00 |
| Total current liabilities | 1.99B |
| Total liabilities | 12.17B |
| Shareholder's equity | 7.60B |
| Net tangible assets | 0.00 |
Cash flow
Loading...
Please create a free account or log in to access this chart
Cash flow data
| Operating cash flow (TTM) | - |
| Capital expenditures (TTM) | - |
| Free cash flow (TTM) | - |
| Dividends paid (TTM) | - |
Financial returns
Loading...
Please create a free account or log in to access this chart
Financial returns data
| Return on Equity | - |
| Return on Assets | - |
| Return on Invested Capital | - |
| Cash Return on Invested Capital | - |
STOCK INFORMATION
Stock chart
Loading...
Stock price data
| Open | 7.85 |
| Daily high | 7.90 |
| Daily low | 7.79 |
| Daily Volume | 288K |
| All-time high | 23.65 |
| 1y analyst estimate | 21.32 |
| Beta | - |
| EPS (TTM) | - |
| Dividend per share | 0.00 |
| Ex-div date | 11 Aug 2025 |
| Next earnings date | 24 Feb 2026 |
Downside potential
Loading...
Downside potential data
| GRF-P.MC | S&P500 | |
| Current price drop from All-time high | -66.77% | -1.08% |
| Highest price drop | -76.09% | -19.00% |
| Date of highest drop | 9 Apr 2025 | 8 Apr 2025 |
| Avg drop from high | -67.63% | -2.64% |
| Avg time to new high | - | 6 days |
| Max time to new high | 302 days | 89 days |
COMPANY DETAILS
Marketcap
-
Marketcap category
Small-cap
Description
Employees
Investor relations
-
SEC filings
CEO
Country
Spain
City
Stock type
-
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
All newsPress releases
European equities traded in the US as American depositary receipts were gaining Wednesday morning, r
December 3, 2025
Iron Mountain Incorporated (NYSE:IRM) is one of the best dividend stocks in the real estate sector. On November 20, Brendan Lynch from Barclays kept a Buy rating on Iron Mountain, along with a target ...
December 2, 2025
Grifols (BME:GRF) shares have continued their recent slide, falling around 13% over the past month. This pullback comes as investors digest current fundamentals and weigh the company's recent performa...
November 20, 2025
The global Guillain-Barré syndrome market is poised for substantial growth, fueled by advancements in treatment options, including intravenous immunoglobulin (IVIg), plasmapheresis, and emerging immun...
November 19, 2025
Grifols S.A. recently reported its Q3 2025 results, with adjusted earnings of €0.21 per share and revenue rising 4% to €1.87 billion, slightly surpassing analyst expectations. Despite exceeding foreca...
November 8, 2025
European equities traded in the US as American depositary receipts were lower late Thursday morning,
November 6, 2025
Grifols (GRFS) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates c...
November 6, 2025
European equities traded in the US as American depositary receipts were tracking higher late Wednesd
November 5, 2025
Grifols SA (GRFS) reports robust year-over-year growth with significant improvements in revenue, EBITDA, and free cash flow, despite facing exchange rate and pricing challenges.
November 5, 2025
Here is how Grifols (GRFS) and Arcutis Biotherapeutics, Inc. (ARQT) have performed compared to their sector so far this year.
October 30, 2025
Next page